Clinical Thyroidology for the Public summarizes selected research studies discussed in the previous month’s issue of Clinical Thyroidology, an official publication of the American Thyroid Association. Editor-in-chief, Alan Farwell, MD, FACE
Volume 9 Issue 12
Available in pdf format for saving and printing and Web page format for viewing online
PDF Format for Saving and Printing
Clinical Thyroidology for the Public Volume 9 Issue 12 (PDF file, 2.35MB)
TABLE OF CONTENTS – Web Format
THYROID CANCER Estrogen status is not associated with increased thyroid cancer risk among postmenopausal women
Luo J et al. Hysterectomy, oophorectomy, and risk of thyroid cancer. J Clin Endocrinol Metab 2016;101:3812-9. Epub July 26, 2016.
(PDF File for saving and printing, 489 KB)
THYROID DISEASE IN THE ELDERLY Abnormal thyroid function is associated with disability risk, but not with increased risk of death, in individuals 85 years of age or older
Pearce SH et al Serum thyroid function, mortality and disability in advanced old age: the Newcastle 85+ study. J Clin Endocrinol Metab 2016. August 23, 2016 [Epub ahead of print].
(PDF File for saving and printing, 539 KB)
HYPOTHYROIDISM AND HYPERTHYROIDISM Thyroid dysfunction and risk of death in patients receiving peritoneal dialysis
Rhee CM et al. Thyroid Functional Disease and Mortality in a National Peritoneal Dialysis Cohort. J Clin Endocrinol Metab. 2016 Nov;101(11):4054-4061.
(PDF File for saving and printing, 532 KB)
THYROID CANCER Ultrasound monitoring of indeterminate neck lesions is safe in some cases of thyroid cancer
Lamartina L et al. Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer. J Clin Endocrinol Metab 2016;1013036-44. Epub May 17, 2016.
(PDF File for saving and printing, 587 KB)
THYROID CANCER Prevalence of thyroid cancer found in autopsy studies has not increased since 1970
Furuya-Kanamori L et al. Prevalence of differentiated thyroid cancer in autopsy studies over six decades: a metaanalysis. J Clin Oncol. September 6, 2016 [Epub ahead of print].
(PDF File for saving and printing, 489 KB)
THYROID CANCER Sorafenib may offer benefits as a second-line treatment of metastatic medullary thyroid cancer
de Castroneves LA et al Sorafenib for the Treatment of progressive metastatic medullary thyroid cancer: efficacy and safety analysis. Thyroid 2016;26:414-9. Epub February 9, 2016.
(PDF File for saving and printing, 582 KB)
ATA ALLIANCE FOR THYROID PATIENT EDUCATION
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.